| Friday, February 27, 2009 |
| 06:00 AM |
|
Panacos Announces Voluntary Decision to Delist Common Stock from Nasdaq and Terminate SEC Registration of Common Stock
|
Business Wire
|
| Monday, February 23, 2009 |
| 04:14 PM |
|
Panacos Pharmaceuticals (PANC) Hires Oppenheimer & Co. to Review Strategic Alternatives; Reduces Workforce
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=4428060 for the full story.
|
StreetInsider
|
| 04:10 PM |
|
Panacos Provides Corporate and Strategic Update
|
Business Wire
|
| Wednesday, February 11, 2009 |
| 04:10 PM |
|
Panacos Announces Additional Personnel Departures
|
Business Wire
|
| Wednesday, January 21, 2009 |
| 06:30 AM |
|
Panacos Announces Sale of Bevirimat
|
Business Wire
|
| 06:30 AM |
|
Myriad Pharmaceuticals Acquires Novel HIV Drug, Bevirimat
Bevirimat, a First-in-Class Maturation Inhibitor, Represents a New Class of HIV Drugs
|
Marketwire
|
| Wednesday, December 10, 2008 |
| 04:05 PM |
|
Panacos Provides Update on Corporate Strategy
|
Business Wire
|
| Saturday, November 22, 2008 |
| 12:00 PM |
|
Panacos Announces Repayment of Hercules Loan
|
Business Wire
|
| Wednesday, November 05, 2008 |
| 04:40 PM |
|
Panacos Pharmaceuticals (PANC) Reports Q3 Loss of $0.15, Beats by 5c
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=4129718 for the full story.
|
StreetInsider
|
| 04:00 PM |
|
Panacos Reports Third Quarter 2008 Financial Results
|
Business Wire
|
| Monday, October 27, 2008 |
| 04:30 PM |
|
Panacos Announces Preliminary Results of Bevirimat Study 204
Results confirm bevirimat tablet formulation dosed twice daily
achieves target plasma levels
|
Business Wire
|
| 04:20 PM |
|
Panacos to Report Third Quarter Results and Provide Development Update
|
Business Wire
|
| Sunday, October 26, 2008 |
| 11:15 AM |
|
Panacos Presents Phase 2b Bevirimat Data at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
|
Business Wire
|
| Tuesday, October 07, 2008 |
| 05:00 PM |
|
Panacos' Study 114 Supports the Company's New Tablet Formulation of Bevirimat
-- 100mg Tablet Formulation will Move Forward in Development --
|
Business Wire
|
| Wednesday, September 10, 2008 |
| 09:40 AM |
|
5 Stocks Approaching Greatness
Investors can find great investments by looking beyond the glare of top-rated stars.
|
Fool.com Headlines
|
| Thursday, July 31, 2008 |
| 11:15 AM |
|
Panacos to Present at Oppenheimer Small and Mid Cap Clinical and Regulatory Conference
|
Business Wire
|
| Wednesday, July 30, 2008 |
| 04:31 PM |
|
Panacos Pharmaceuticals, Inc. (PANC) Reports Q3 In-Line
Visit StreetInsider.com at http://www.streetinsider.com/news.php?st=p&id=3861996 for the full story.
|
StreetInsider
|
| 04:00 PM |
|
Panacos Reports Second Quarter 2008 Financial Results
|
Business Wire
|
| Tuesday, July 29, 2008 |
| 03:50 PM |
|
Panacos Announces Stock Listing Transfer to The Nasdaq Capital Market
|
Business Wire
|
| Monday, July 28, 2008 |
| 06:30 PM |
|
Panacos to Present Clinical Data on Bevirimat at the 48th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
|
Business Wire
|
| |
More All For PANC
|
|
